Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice.
Muscarinic acetylcholine receptors (M(1)-M(5)) regulate many key functions of the central and peripheral nervous system. Primarily because of the lack of receptor subtype-selective ligands, the precise physiological roles of the individual muscarinic receptor subtypes remain to be elucidated. Interestingly, the M(4) receptor subtype is expressed abundantly in the striatum and various other forebrain regions. To study its potential role in the regulation of locomotor activity and other central functions, we used gene-targeting technology to create mice that lack functional M(4) receptors. Pharmacologic analysis of M(4) receptor-deficient mice indicated that M(4) receptors are not required for muscarinic receptor-mediated analgesia, tremor, hypothermia, and salivation. Strikingly, M(4) receptor-deficient mice showed an increase in basal locomotor activity and greatly enhanced locomotor responses (as compared with their wild-type littermates) after activation of D1 dopamine receptors. These results indicate that M(4) receptors exert inhibitory control on D1 receptor-mediated locomotor stimulation, probably at the level of striatal projection neurons where the two receptors are coexpressed at high levels. Our findings offer new perspectives for the treatment of Parkinson's disease and other movement disorders that are characterized by an imbalance between muscarinic cholinergic and dopaminergic neurotransmission.
Gomeza
J
J
Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USA.
Zhang
L
L
Kostenis
E
E
Felder
C
C
Bymaster
F
F
Brodkin
J
J
Shannon
H
H
Xia
B
B
Deng
C
C
Wess
J
J
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000494:pharmacology; D000698:Analgesia; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001921:Brain / Q000502:physiology*; D003342:Corpus Striatum / Q000502:physiology; D018491:Dopamine Agonists / Q000494:pharmacology; D007035:Hypothermia / Q000503:physiopathology; D051379:Mice; D018345:Mice, Knockout; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology*; D010095:Oxotremorine / Q000494:pharmacology*; D016548:Prosencephalon / Q000502:physiology; D019257:Quinpirole / Q000494:pharmacology; D011869:Radioligand Assay; D043588:Receptor, Muscarinic M4; D017447:Receptors, Dopamine D1 / Q000502:physiology*; D011976:Receptors, Muscarinic / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D012472:Salivation / Q000187:drug effects; D014202:Tremor / Q000139:chemically induced / Q000503:physiopathology
D018491:Dopamine Agonists; D043588:Receptor, Muscarinic M4; D017447:Receptors, Dopamine D1; D011976:Receptors, Muscarinic; D019257:Quinpirole; D010095:Oxotremorine; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D001058:Apomorphine